Aisling Capital Partners IV, LP is 10% at Elevation Oncology, Inc. (ELEV). They have made 2 open-market trades across 2 companies since 2019, most recently 2021-06-29.
CIK 0001737020
2 open-market purchases totalling $4.5M since 2019, never a sale. Too few scored purchases to measure a record yet.
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.